Pre- and post-ASCT CR rate with novel induction regimens
| Regimen . | Pre-ASCT, % . | Post-ASCT, % . |
|---|---|---|
| Thalidomide/dexamethasone | 6 | 23-34 |
| Bortezomib/dexamethasone | 12 | 33 |
| PAD-1 | 24 | 43 |
| VTD | 21-30 | 43-49 |
| Total Therapy III | — | 56 (2 y) |
| Regimen . | Pre-ASCT, % . | Post-ASCT, % . |
|---|---|---|
| Thalidomide/dexamethasone | 6 | 23-34 |
| Bortezomib/dexamethasone | 12 | 33 |
| PAD-1 | 24 | 43 |
| VTD | 21-30 | 43-49 |
| Total Therapy III | — | 56 (2 y) |
ASCT indicates autologous stem cell transplantation; CR, complete remission; PAD, bortezomib PS 341, adriamycin, dexamethasone; VTD, bortezomib/thalidomide/dexamethasone; and —, not applicable.